Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | ALB | P02768 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | TK1 | P04183 | 5/20 | 0.39 |
| ▸ | TK2 | O00142 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7025003 | 0.91 | LMNA (0.39) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL6909597 | 0.90 | TK2 (0.38) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL6663227 | 0.89 | TK1 (0.39) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL8003522 | 0.89 | LMNA (0.37) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL18642515 | 0.86 | TK1 (0.46) | POLBTK1 | |
| SCHEMBL23883671 | 0.82 | TK1 (0.37) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL18660220 | 0.81 | SLC28A1 (0.44) | — | |
| SCHEMBL28361568 | 0.81 | TK1 (0.41) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL27349255 | 0.80 | TK1 (0.42) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL18007504 | 0.80 | ADORA2A (0.31) | LMNABLMALDH1A1POLBPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025201529-A1 | COMPOUNDS FOR SYNTHESIZING MODIFIED SMALL ACTIVATING RNA MOLECULES, MODIFIED SMALL ACTIVATING RNA MOLECULES AND USES THEREOF | RACTIGEN THERAPEUTICS (CN) | 2025-10-02 | — | — | WO | disclosed |
| WO-2024123842-A1 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | EDITAS MEDICINE, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| EP-4381068-A1 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | Editas Medicine, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| WO-2024102860-A1 | ENGINEERED CELLS FOR THERAPY | SHORELINE BIOSCIENCES, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| EP-4346877-A2 | ENGINEERED CELLS FOR THERAPY | Shoreline Biosciences, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2023220206-A2 | GENOME EDITING OF B CELLS | EDITAS MEDICINE, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220207-A2 | GENOME EDITING OF CELLS | EDITAS MEDICINE, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023176862-A1 | siRNA FOR SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR-2 | 第一三共株式会社 | 2023-09-21 | — | — | WO | disclosed |
| WO-2023176863-A1 | CHEMICALLY-MODIFIED OLIGONUCLEOTIDE HAVING RNAI ACTIVITY | 第一三共株式会社 | 2023-09-21 | — | — | WO | disclosed |
| WO-2023097316-A1 | ENGINEERED CRISPR/CAS12A EFFECTOR PROTEINS, AND USES THEREOF | EDITAS MEDICINE, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2019217397-A2 | COMPOSITIONS AND METHODS FOR IMPROVING STRAND BIASED | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-11-14 | — | — | WO | disclosed |
| EP-3544617-A1 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | Alnylam Pharmaceuticals, Inc. (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-3433363-A1 | GENOME EDITING SYSTEMS COMPRISING REPAIR-MODULATING ENZYME MOLECULES AND METHODS OF THEIR USE | Editas Medicine, Inc. (US) | 2019-01-30 | — | — | EP | disclosed |
| CN-108699557-A | Composition for oncology to be immunized and method | 诺华股份有限公司 | 2018-10-23 | — | — | CN | disclosed |
| WO-2018170184-A1 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | EDITAS MEDICINE, INC. (US) | 2018-09-20 | — | — | WO | disclosed |
| EP-3329002-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES | Alnylam Pharmaceuticals, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| WO-2018098328-A1 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| WO-2017165826-A1 | GENOME EDITING SYSTEMS COMPRISING REPAIR-MODULATING ENZYME MOLECULES AND METHODS OF THEIR USE | EDITAS MEDICINE, INC. (US) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017023660-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2003074656-A2 | RANK-LIGAND-INDUCED SODIUM/PROTON ANTIPORTER POLYPEPTIDES | IMMUNEX CORPORATION (US) | 2003-09-12 | — | — | WO | disclosed |